Impacting Cancer

Nextech Invest, May 2017
Is this email not displaying correctly?
View it in your browser.

Dear Reader, 

We congratulate David M. Livingston, MD, Emil Frei Professor of Genetics & Medicine, Dana-Farber Cancer Institute, Deputy Director of the Dana-Farber/Harvard Cancer Center and chairman of the Nextech Scientific Board, to receiving the Pezcoller Foundation-AACR International Award for Cancer Research. In an exclusive interview, Hugh O'Dowd, CEO of Neon Therapeutics, introduces one of the leading companies in the development of personalized cancer therapies based on neoantigens that is the latest addition to the portfolio of Nextech. In this edition of Nextech Insights, Rocco J. Sgobbo reviews the recent M&A activity in oncology.

With kind regards, 
The Nextech Team

Interview

Unlocking the immune system

Hugh O'Dowd, CEO of Neon Therapeutics, talks about the move from Big Pharma to Biotech and how Neon is leading the drive for novel neoantigen targeted therapies in this Nextech exclusive interview. 

Read the interview

Nextech Invest News

Award-winning research 

Dr. David Livingston, chairman of the Nextech Scientific Board, received the 2017 Pezcoller Foundation-AACR International Award for Cancer Research for his work on cell-cycle control and tumor suppressor genes, namely BRCA.

Read the details.

Nextech Insights

Oncology firms lead a robust biotech M&A market 

In this edition of Nextech Insights, Rocco J. Sgobbo, Head of Business Development at Nextech Invest, takes a closer look at the factors driving the robust biotech M&A activity and why oncology companies are in the spotlight.

Read the article.

Nextech launches its presence on Twitter. To stay up to date on the latest topics in oncology investing, follow us on Twitter.
@NextechInvest

Peloton Therapeutics appointed Mohammad Hirmand, MD, as Chief Medical Officer.

Read the press release.

Peloton Therapeutics extended the Series D to USD 74.6m in total.

Read the press release.

Blueprint Medicines [BPMC] announced the enrollment of the first patient in the Phase I clinical trial of BLU-667.

Read the press release.

In March 2017, Blueprint Medicines raised USD 215 million from a public offering of common stock.

Read the press release.

Kura Oncology [KURA] dosed first patients in the Phase I clinical trial of ERK inhibitor KO-947 in advanced solid tumors.

Read the press release.

Tracon Pharmaceuticals [TCON] initiated the Phase III TAPPAS clinical trial of TRC-105 in angiosarcoma and presented results from the Phase II clinical trial of TRC-105 in glioblastoma.

In March 2017, Tracon announced a USD 21 million stock purchase agreement with Aspire Capital. 

Read the press releases

Impressum
Nextech Invest Ltd.
Turnerstrasse 26
8006 Zurich, Switzerland

Web: www.nextechinvest.com
E-Mail: info@nextechinvest.com